Vaxart Inc (VXRT)
0.836
-0.03
(-3.48%)
USD |
NASDAQ |
Apr 18, 16:00
0.8423
+0.01
(+0.75%)
After-Hours: 20:00
Vaxart Cash from Financing (TTM): 15.24M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 15.24M |
September 30, 2023 | 23.90M |
June 30, 2023 | 28.90M |
March 31, 2023 | 17.84M |
December 31, 2022 | 17.46M |
September 30, 2022 | 9.371M |
June 30, 2022 | 25.03M |
March 31, 2022 | 59.25M |
December 31, 2021 | 125.80M |
September 30, 2021 | 130.40M |
June 30, 2021 | 208.37M |
March 31, 2021 | 186.36M |
December 31, 2020 | 138.31M |
September 30, 2020 | 130.99M |
June 30, 2020 | 40.13M |
March 31, 2020 | 33.38M |
December 31, 2019 | 15.96M |
September 30, 2019 | 17.67M |
June 30, 2019 | 9.446M |
March 31, 2019 | 0.659M |
December 31, 2018 | -1.729M |
September 30, 2018 | -1.21M |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | 17.80M |
March 31, 2016 | -0.30M |
December 31, 2015 | -0.20M |
September 30, 2015 | -0.20M |
June 30, 2015 | -0.10M |
March 31, 2015 | 0.00 |
December 31, 2014 | 26.80M |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | -24.46M |
June 30, 2012 | 0.138M |
March 31, 2012 | 0.368M |
December 31, 2011 | 0.663M |
September 30, 2011 | 0.873M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
9.371M
Minimum
Sep 2022
208.37M
Maximum
Jun 2021
64.94M
Average
28.90M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
aTyr Pharma Inc | 66.23M |
Allogene Therapeutics Inc | 95.70M |
AIM ImmunoTech Inc | 0.485M |
Protalix BioTherapeutics Inc | 24.67M |
Armata Pharmaceuticals Inc | 53.99M |